Your browser is no longer supported. Please, upgrade your browser.
TOCA Tocagen Inc. daily Stock Chart
TOCA [NASD]
Tocagen Inc.
Index- P/E- EPS (ttm)-3.21 Insider Own6.41% Shs Outstand11.32M Perf Week331.73%
Market Cap23.66M Forward P/E- EPS next Y-0.99 Insider Trans0.00% Shs Float- Perf Month261.90%
Income-72.50M PEG- EPS next Q-0.57 Inst Own25.10% Short Float- Perf Quarter231.75%
Sales0.04M P/S657.19 EPS this Y8.40% Inst Trans-22.84% Short Ratio0.99 Perf Half Y-53.56%
Book/sh0.83 P/B2.52 EPS next Y65.20% ROA-82.00% Target Price1.00 Perf Year-80.86%
Cash/sh4.89 P/C0.43 EPS next 5Y- ROE-182.20% 52W Range0.42 - 12.00 Perf YTD291.97%
Dividend- P/FCF- EPS past 5Y-29.40% ROI-56.40% 52W High-85.58% Beta-
Dividend %- Quick Ratio1.40 Sales past 5Y188.70% Gross Margin- 52W Low309.95% ATR0.23
Employees85 Current Ratio1.40 Sales Q/Q-100.00% Oper. Margin- RSI (14)75.11 Volatility66.57% 22.59%
OptionableYes Debt/Eq1.40 EPS Q/Q- Profit Margin- Rel Volume3.30 Prev Close2.09
ShortableYes LT Debt/Eq0.00 EarningsMar 04 AMC Payout- Avg Volume2.07M Price1.73
Recom3.00 SMA20158.11% SMA50193.66% SMA200-37.08% Volume4,216,280 Change-17.22%
Sep-13-19Downgrade Citigroup Buy → Neutral
Sep-13-19Downgrade Chardan Capital Markets Buy → Neutral
Sep-12-19Downgrade Ladenburg Thalmann Buy → Neutral
Sep-12-19Downgrade H.C. Wainwright Buy → Neutral
Sep-12-19Downgrade Evercore ISI Outperform → In-line
Sep-12-19Downgrade Cantor Fitzgerald Overweight → Neutral $28 → $1
May-30-19Resumed Citigroup Buy
Apr-26-19Initiated Cantor Fitzgerald Overweight $28
Apr-15-19Initiated SVB Leerink Mkt Perform $11
Jan-18-19Initiated Robert W. Baird Outperform $20
Dec-31-18Resumed B. Riley FBR Buy $22
Aug-30-18Initiated Chardan Capital Markets Buy $30
Feb-20-20 07:06AM  The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study Benzinga +85.45%
Feb-19-20 08:13PM  Tocagen and Forte Biosciences Announce Merger PR Newswire -10.71%
Jan-17-20 09:55AM  Introducing Tocagen (NASDAQ:TOCA), The Stock That Tanked 94% Simply Wall St. +6.86%
Dec-23-19 02:55PM  Is Tocagen Inc. (TOCA) A Good Stock To Buy? Insider Monkey -9.00%
Nov-22-19 04:05PM  Toca 5 Phase 3 Trial Results Presented at the Society for Neuro-Oncology Annual Meeting PR Newswire +20.79%
Nov-12-19 04:30PM  Tocagen Reports Third Quarter 2019 Financial Results and Business Updates PR Newswire
06:15AM  MDNA.TO: Additional MDNA55 Data to be Presented at Society for NeuroOncology Annual Meeting Nov 20-24, 2019 Zacks Small Cap Research
Nov-08-19 08:00AM  Tocagen Highlights Toca 6 Phase 1b Data at Society for Immunotherapy of Cancer Annual Meeting PR Newswire
Nov-06-19 04:05PM  Tocagen to Report Third Quarter 2019 Financial Results and Business Updates on Tuesday, November 12 PR Newswire
Oct-28-19 08:00AM  MDNA.TO: Financing Extends Cash Runway Through 2020; Multiple Catalysts on the Horizon Zacks Small Cap Research +8.68%
Oct-03-19 08:00AM  Tocagen Announces Restructuring to Focus on Clinical Development PR Newswire +19.68%
Sep-30-19 06:45AM  MDNA.TO: Increased Overall Survival in rGBM Patients Seen with High Dose MDNA55 Zacks Small Cap Research
Sep-13-19 07:40AM  The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans Benzinga +10.72%
Sep-12-19 09:24AM  Tocagen Shares Plummet On Failed Late-Stage Brain Cancer Study Benzinga -77.74%
08:17AM  Tocagen's stock plunges toward record low after late-stage trial of cancer treatment misses primary endpoint MarketWatch
07:38AM  The Daily Biotech Pulse: Ardelyx Awaits Ruling On Constipation Drug, Double Dose Of Good News For Roche, Tocagen Flunks Brain Cancer Study Benzinga
06:44AM  UPDATE 2-Tocagen's brain cancer treatment fails late-stage study, shares crash Reuters
06:00AM  Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer PR Newswire
Sep-05-19 08:44AM  Implied Volatility Surging for Tocagen (TOCA) Stock Options Zacks
Aug-26-19 08:00AM  Tocagen to Participate in Two Upcoming Investor Conferences PR Newswire -6.52%
Aug-16-19 03:29PM  Did Tocagen Inc. (NASDAQ:TOCA) Insiders Buy Up More Shares? Simply Wall St.
Aug-01-19 04:05PM  Tocagen to Report Second Quarter 2019 Financial Results and Business Updates on Thursday, August 8 PR Newswire
Jul-30-19 10:38AM  TOCAGEN INC (TOCA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Jun-27-19 02:00PM  Could The Tocagen Inc. (NASDAQ:TOCA) Ownership Structure Tell Us Something Useful? Simply Wall St.
Jun-21-19 08:40AM  Do Options Traders Know Something About Tocagen (TOCA) Stock We Don't? Zacks
May-30-19 08:00AM  Tocagen to Present at Upcoming Jefferies 2019 Healthcare Conference PR Newswire +21.33%
May-22-19 01:19PM  Here's Why Tocagen's Having a Rough Day Motley Fool -38.66%
07:34AM  The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study Benzinga
May-21-19 04:05PM  Tocagen's Toca 5 Pivotal Phase 3 Clinical Trial in Patients with Recurrent Brain Cancer Continues Without Modification at Planned Interim Analysis PR Newswire
May-07-19 04:01PM  Tocagen Reports First Quarter 2019 Financial and Business Results PR Newswire
08:56AM  Are Options Traders Betting on a Big Move in Tocagen (TOCA) Stock? Zacks
Apr-30-19 04:01PM  Tocagen to Report First Quarter 2019 Financial and Business Results on Tuesday, May 7 PR Newswire
Apr-15-19 08:00AM  Tocagen Appoints Fairooz Kabbinavar, M.D., FACP, as Senior Vice President, Clinical Development PR Newswire
Mar-27-19 10:49AM  Tocagen to Present Updated Data from Clinical and Preclinical Studies at Two Scientific Conferences PR Newswire
Mar-11-19 08:44AM  Implied Volatility Surging for Tocagen (TOCA) Stock Options Zacks
Feb-27-19 04:01PM  Tocagen Reports Fourth Quarter and Full Year 2018 Financial and Business Results PR Newswire
Feb-20-19 06:22PM  Tocagen to Report Fourth Quarter and Full Year Financial Results on Wednesday, February 27 and Present at Upcoming SVB Leerink Global Healthcare Conference PR Newswire
Feb-04-19 07:35AM  Analysis: Positioning to Benefit within Amarin, Retrophin, Sunrun, BioSpecifics Technologies, Arbutus Biopharma, and TOCAGEN INC Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Dec-13-18 04:25PM  Here's Why Tocagen Is Sliding Today Motley Fool -11.40%
Dec-12-18 07:00PM  Tocagen Announces Pricing of Public Offering of Common Stock PR Newswire -12.40%
Dec-11-18 05:08PM  Tocagen Announces Proposed Public Offering of Common Stock PR Newswire
Nov-29-18 08:00AM  Tocagen and NRG Oncology to Collaborate on a Phase 2/3 Trial of Toca 511 & Toca FC in Newly Diagnosed Glioblastoma PR Newswire
07:30AM  Investor Expectations to Drive Momentum within ANSYS, Nordic American Tankers, Woodward, GW Pharmaceuticals, CareTrust REIT, and TOCAGEN INC Discovering Underlying Factors of Influence GlobeNewswire
Nov-15-18 04:01PM  Tocagen Appoints Lori Kunkel, M.D. as Acting Chief Medical Officer PR Newswire
Nov-08-18 04:01PM  Tocagen Reports Third Quarter 2018 Financial and Business Results PR Newswire
Nov-07-18 04:01PM  Tocagen to Participate in Investor Conferences in November PR Newswire
Nov-06-18 08:00AM  Tocagen to Present Updated Data from Clinical and Preclinical Studies at Three Scientific and Medical Conferences PR Newswire
Nov-01-18 04:01PM  Tocagen to Report Third Quarter 2018 Financial Results on Thursday, November 8 PR Newswire +8.13%
Oct-22-18 08:55AM  Factors of Influence in 2018, Key Indicators and Opportunity within Wix, Darden Restaurants, Dollar General, TOCAGEN INC, Burlington Stores, and McCormick & Company New Research Emphasizes Economic Growth GlobeNewswire
Oct-15-18 10:30AM  Cancer Companies to Watch ACCESSWIRE
Oct-02-18 08:00AM  Tocagen Provides Update on European Regulatory Path for Toca 511 & Toca FC PR Newswire
01:17AM  Tocagen Presents Preliminary Data from Toca 6 Trial Supportive of Immune Activation in Patients with Advanced Solid Tumors at CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference PR Newswire
Sep-27-18 04:33PM  Tocagen to Participate in Four Investor Conferences in October PR Newswire
Sep-24-18 08:00AM  Tocagen Appoints Mohamed Ladha as Vice President to Establish Commercial Organization PR Newswire
Sep-19-18 08:00AM  Tocagen Announces Early Completion of Enrollment in Toca 5 Pivotal Phase 3 Brain Cancer Trial PR Newswire +6.47%
Sep-08-18 07:22AM  3 Biotech Stocks That Could Double Your Money Motley Fool
Aug-30-18 01:38PM  A Lesson to Learn From Thursday's Market Action TheStreet.com +10.73%
09:38AM  Chardan: Tocagen's Brain, Spinal Cord Tumor Candidate Has $877M Potential Benzinga
Aug-28-18 04:05PM  Tocagen to Participate in Two Investor Conferences Next Week PR Newswire
Aug-23-18 08:00AM  Tocagen's Toca 5 Pivotal Phase 3 Clinical Trial in Patients with Recurrent Brain Cancer Continues Without Modification at Planned First Interim Analysis PR Newswire
Aug-07-18 04:05PM  Tocagen Reports Second Quarter 2018 Financial and Business Results PR Newswire
Aug-01-18 04:05PM  Tocagen to Report Second Quarter 2018 Financial Results on Tuesday, August 7 PR Newswire
Jul-09-18 08:00AM  Tocagen Closes Previously Announced License Agreement with ApolloBio to Develop and Commercialize Toca 511 & Toca FC in Greater China PR Newswire
May-24-18 07:40AM  Report: Exploring Fundamental Drivers Behind TOCAGEN INC, Jones Lang LaSalle, Movado Group, Liberty Media, First, and WEX New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
May-16-18 12:27PM  B Riley Likes Tocagen On Prospects For Company's Brain Cancer Drug Benzinga
May-14-18 08:00AM  Tocagen to Present Preclinical Data on Anti-PD-L1 Product Candidate Toca 521 at the 2018 Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) PR Newswire
May-10-18 04:05PM  Tocagen Reports First Quarter 2018 Financial and Business Results PR Newswire
May-03-18 04:05PM  Tocagen to Report First Quarter 2018 Financial Results on Thursday, May 10 PR Newswire
Apr-19-18 08:00AM  Tocagen and ApolloBio Enter License Agreement to Develop and Commercialize Toca 511 & Toca FC in the Greater China Region PR Newswire
Apr-17-18 08:00AM  Tocagen to Present Updated Clinical and Preclinical Data at Three Scientific Conferences PR Newswire
Apr-16-18 09:00AM  Tocagen Presents Preliminary Toca 6 Phase 1 Data in Patients with Advanced Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting 2018 PR Newswire -6.48%
Apr-02-18 08:25AM  New Research Coverage Highlights TOCAGEN INC, Acer Therapeutics, DMC Global, The Providence Service, WEX, and Alexander's Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Mar-15-18 08:00AM  Tocagen to Present Preliminary Toca 6 Phase 1 Data and Immune Profiling Data at the American Association for Cancer Research (AACR) Annual Meeting 2018 PR Newswire
Mar-13-18 08:00AM  Tocagen to Present at the B. Riley FBR China Healthcare Investment & Partnering Symposium 2018 PR Newswire -5.26%
Mar-08-18 04:05PM  Tocagen Reports Fourth Quarter and Full Year 2017 Financial and Business Results PR Newswire
Mar-07-18 08:00AM  Tocagen Receives European Medicines Agency Orphan Medicinal Product Designation for Toca 511 & Toca FC for the Treatment of Glioma PR Newswire
Mar-01-18 08:00AM  Tocagen to Report Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Progress on Thursday, March 8 PR Newswire
Feb-07-18 08:00AM  Tocagen to Present at Leerink Partners 7th Annual Global Healthcare Conference PR Newswire
Jan-30-18 08:20AM  New Research: Key Drivers of Growth for VAREX IMAGING, DCP Midstream Partners, LP, Werner Enterprises, K12, RA PHARMCTL INC, and TOCAGEN INC Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Dec-14-17 08:00AM  Tocagen Added to NASDAQ Biotechnology Index PR Newswire
Nov-21-17 04:05PM  Tocagen Announces Time Change for Presentation at Evercore ISI Biopharma Catalyst/Deep Dive Conference PR Newswire
Nov-10-17 08:00AM  Tocagen to Present at Two Investor Conferences in November PR Newswire
Nov-09-17 08:00AM  Tocagen to Present Updated Clinical and Preclinical Data at Three Scientific Conferences PR Newswire
Nov-08-17 04:05PM  Tocagen Reports Third Quarter 2017 Financial and Business Results PR Newswire
Nov-02-17 04:52PM  Are Tocagen Incs (TOCA) Interest Costs Too High? Simply Wall St.
Nov-01-17 04:05PM  Tocagen to Report Third Quarter 2017 Financial Results on Wednesday, November 8 PR Newswire
Oct-27-17 09:15AM  Tocagen Presents Updated Durable Complete Response Data from Phase 1 Trial of Toca 511 & Toca FC in Recurrent High-Grade Glioma PR Newswire
Oct-26-17 04:05PM  Tocagen to Accelerate Toca 511 & Toca FC Development into Pivotal Phase 3 Trial PR Newswire
Oct-17-17 08:00AM  Tocagen to Present Updated Durable Response Data from Phase 1 Trial of Toca 511 & Toca FC in Recurrent Brain Cancer at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics PR Newswire
Aug-09-17 05:07PM  Tocagen Reports Second Quarter 2017 Financial and Business Results PR Newswire
Aug-02-17 04:05PM  Tocagen to Report Second Quarter 2017 Financial Results on Wednesday, August 9 PR Newswire
Jul-24-17 08:00AM  Tocagen Receives European Medicines Agency Priority Medicines (PRIME) Designation for Toca 511 in High Grade Glioma PR Newswire
Jun-19-17 08:00AM  Complementary Preclinical Studies Published in Neuro-Oncology Demonstrate Immune Activation Mechanism of Tocagen's Toca 511 & Toca FC PR Newswire
May-23-17 04:05PM  Tocagen Reports First Quarter 2017 Financial and Business Results PR Newswire
May-11-17 08:00AM  Tocagen Presents Data at the American Society of Gene and Cell Therapy 20th Annual Meeting PR Newswire
Apr-19-17 04:05PM  Tocagen Announces Closing of Initial Public Offering and Exercise of the Underwriters' Option PR Newswire
Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California.